Phospho-YAP1(Ser127) Antibody (YA5859)

Cat. No.: HY-P86167: Data Sheet User Guide for Antibodies
FAQs
Technical Support

Phospho-YAP1(Ser127) Antibody (YA5859) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-YAP1(Ser127).

For research use only. We do not sell to patients.

Size	Stock	Quantity
20 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 μL	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
250 μL	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

Phospho-YAP1(Ser127) Antibody (YA5859) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-YAP1(Ser127).

Host

Rabbit

Clonality

Monoclonal

Molecular Weight

Predicted band size: 55 kDa;

Observed band size: 55 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human, Mouse, Rat

SwissProt ID

P46937

Gene ID

10413 [NCBI]

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:2000-1:10000
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:200-1:1000
ELISA ELISA: Enzyme Linked Immunosorbent Assay	1:5000-1:20000
IP IP: Immunoprecipitation	1:50-1:200

Purity	Protein A	Conjugation	Non-conjugated
Modification	Phosphorylated	Isotype	IgG

Appearance

Liquid

Formulation

Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Transcriptional regulator with dual roles as a coactivator and corepressor. Critical downstream regulatory target in the Hippo signaling pathway, crucial for organ size control and tumor suppression by restricting proliferation and promoting apoptosis (PubMed:17974916, PubMed:18280240, PubMed:18579750, PubMed:21364637, PubMed:30447097). The Hippo signaling pathway core involves a kinase cascade featuring STK3/MST2 and STK4/MST1, along with its regulatory partner SAV1, which phosphorylates and activates LATS1/2 in complex with their regulatory protein, MOB1. This activation leads to the phosphorylation and inactivation of the YAP1 oncoprotein and WWTR1/TAZ (PubMed:18158288). Phosphorylation of YAP1 by LATS1/2 prevents its nuclear translocation, thereby regulating the expression of its target genes (PubMed:18158288, PubMed:26598551, PubMed:34404733). The transcriptional regulation of gene expression requires TEAD transcription factors and modulates cell growth, anchorage-independent growth, and induction of epithelial-mesenchymal transition (EMT) (PubMed:18579750). Plays a key role in tissue tension and 3D tissue shape by regulating the cortical actomyosin network, acting via ARHGAP18, a Rho GTPase activating protein that suppresses F-actin polymerization (PubMed:25778702). It also suppresses ciliogenesis by acting as a transcriptional corepressor of TEAD4 target genes AURKA and PLK1 (PubMed:25849865). In conjunction with WWTR1, regulates TGFB1-dependent SMAD2 and SMAD3 nuclear accumulation (By similarity). Synergizes with WBP2 to enhance PGR activity (PubMed:16772533); Activates the C-terminal fragment (CTF) of ERBB4 (isoform 3); Activates the C-terminal fragment (CTF) of ERBB4 (isoform 3)

Subcellular Localization：Cytoplasm; Nucleus; Cell junction, tight junction; Cell membrane

Expression：
Tissue_specificity:Increased expression has been observed in certain liver and prostate cancers. A subtype (protein level) lacking the transcriptional activation domain has been found in striatal neurons of Huntington's disease.

Induction:Induced in the hours following cyclic mechanical strain in keratinocytes

Isoforms & Post-Translational Modification：P46937 has 9 isomers: P46937-1: 54462 Da (predicted); P46937-2: 52748 Da (predicted); P46937-3: 48755 Da (predicted); P46937-4: 36232 Da (predicted); P46937-5: 48275 Da (predicted); P46937-6: 49989 Da (predicted); P46937-7: 50469 Da (predicted); P46937-8: 53228 Da (predicted); P46937-9: 54942 Da (predicted).
Phosphorylated by LATS1 and LATS2; leading to cytoplasmic translocation and inactivation (PubMed:18158288, PubMed:20048001). Phosphorylated by ABL1; leading to YAP1 stabilization, enhanced interaction with TP73 and recruitment onto proapoptotic genes; in response to DNA damage (PubMed:18280240). Phosphorylation at Ser-400 and Ser-403 by CK1 is triggered by previous phosphorylation at Ser-397 by LATS proteins and leads to YAP1 ubiquitination by SCF(beta-TRCP) E3 ubiquitin ligase and subsequent degradation (PubMed:20048001). Phosphorylated at Thr-119, Ser-138, Thr-154, Ser-367 and Thr-412 by MAPK8/JNK1 and MAPK9/JNK2, which is required for the regulation of apoptosis by YAP1 (PubMed:21364637). Phosphorylated in the nucleus by PRP4K; phosphorylation leads to nuclear exclusion (PubMed:29695716);Lactylation by AARS1 promotes nuclear localization and stabilization of YAP1, leading to increased Hippo signaling pathway (PubMed:38512451). Delactylated by SIRT1 (PubMed:38512451);Ubiquitinated by SCF(beta-TRCP) E3 ubiquitin ligase

Subunit：Part of a complex when phosphorylated that contains DSG3, PKP1, YAP1 and YWHAG; the complex is required for localization of DSG3 and YAP1 to the cell membrane in keratinocytes (PubMed:31835537). Binds to the SH3 domain of the YES kinase. Binds to WBP1 and WBP2 (PubMed:9202023). Binds, in vitro, through the WW1 domain, to neural isoforms of ENAH that contain the PPSY motif (By similarity). The phosphorylated form interacts with YWHAB (PubMed:17974916). Interacts (via WW domains) with LATS1 (via PPxY motif 2) (PubMed:18158288). Interacts with LATS2 (PubMed:18158288). Interacts with TEAD1, TEAD2, TEAD3 and TEAD4 (PubMed:18579750, PubMed:20123905, PubMed:20123908). Interacts with TP73 (PubMed:18280240). Interacts with RUNX1 (PubMed:18280240). Interacts with HCK (PubMed:17535448). Interacts (via WW domains) with PTPN14 (via PPxY motif 2); this interaction leads to the cytoplasmic sequestration of YAP1 and inhibits its transcriptional coactivator activity (PubMed:22525271). Interacts (when phosphorylated at Ser-127) with SMAD2, SMAD3 and WWTR1 (By similarity). Interacts with PRRG2 (via cytoplasmic domain) (PubMed:17502622). Interacts (via WW domains) with PRRG4 (via cytoplasmic domain) (PubMed:23873930). Interacts (phosphorylated) with CLDN18; the interaction sequesters YAP1 away from the nucleus and thereby restricts transcription of YAP1 target genes (By similarity). Interacts with SMAD1 (PubMed:21685363). Interacts with AMOTL2, the interaction is required for ubiquitination of AMOTL2 and localization of YAP1 to tight junctions (PubMed:21205866, PubMed:26598551). Interacts with AMOT isoform 1; the interaction facilitates translocation of YAP1 to the cytoplasm and tight junctions (PubMed:21205866)

Synonyms

YAP1; YAP65; Yorkie homolog; 65 kDa Yes-associated protein; YAP65

Documentation

User Guide for Antibodies (1077 KB)